The new, proprietary target discovery platform integrates RWD, human biological modeling, and CRISPR screens to accelerate novel target identification CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ ...

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal ...

In the last three months, 9 analysts have published ratings on Tempus AI TEM, offering a diverse range of perspectives from bullish to bearish. The table below provides a snapshot of their recent ...

The companies will use the AI-based platform to accelerate cancer drug discovery. Credit: sanjeri via Getty Images. AstraZeneca, Tempus and Pathos AI have signed a multi-year agreement to develop a ...

The platform enables an understanding of the interactions between T cell receptors and their corresponding antigenic epitopes. Credit: THICHA SATAPITANON / Shutterstock. Repertoire Immune Medicines ...

Investing.com -- Tempus AI Inc (NASDAQ:TEM) shares closed up 14.5% following the announcement of expanded strategic partnerships with AstraZeneca (NASDAQ:AZN) and Pathos AI, Inc. The ...

Tempus AI shares were 14% higher, at $49.35, after the company said it has entered into multi-year strategic collaborations with AstraZeneca and Pathos AI. The technology company said the ...

Shares of Tempus AI (NASDAQ: TEM) were skyrocketing 16.5% higher as of 10:39 a.m. ET on Wednesday. The big gain came after the healthcare artificial intelligence (AI) company announced a multiyear ...

Tempus AI (Nasdaq: TEM) and D-Wave Quantum (NYSE: QBTS) are up by double-digit percentages today while Rigetti Computing (Nasdaq: RGTI) is enjoying a nice pop amid signs AI and the quantum ...

Tempus AI also announced a promising new partnership with AstraZeneca and Pathos AI to aid cancer research and treatment. Tempus AI could have an incredible runway for growth, but its valuation ...